Development and external validation of a machine learning model to predict central sensitization symptom burden in psoriatic arthritis
Frontiers in Immunology · 19.11.2026 · 17
DOI: 10.3389/fimmu.2026.2013699 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 19.11.2026. Verfasst von Leonardo Frascà und 22 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Central sensitization (CS) is a general mechanism of pain amplification. In psoriatic arthritis (PsA), it contributes to pain that is disproportionate to inflammation. We aimed to develop and externally validate machine learning (ML) models to identify clinically significant central sensitization symptom burden in PsA from routinely available clinical and patient-reported variables.
Methods
Models were developed in a cohort of 223 patients with PsA (CASPAR criteria) and externally validated in 50 patients from two referral centers. The outcome was a Central Sensitization Inventory (CSI) total score ≥40. Logistic Regression (LR) and Random Forest (RF) were developed using nested 5-fold stratified cross-validation with model-specific regularisation. The final models were then refitted on the entire development cohort, recalibrated using logistic recalibration, and independently evaluated in the external validation cohort.
Results
Elevated CS symptom burden (CSI ≥40) was present in 63.7% of patients internally and 70% externally. Both models discriminated well internally (AUROC 0.83 LR, 0.81 RF) and externally (AUROC 0.78, 95% CI 0.65–0.90, LR; 0.84, 95% CI 0.72–0.93, RF), with comparable performance between models, and were adequately calibrated after recalibration, with wider uncertainty in the external cohort. The main predictors, consistent across both models, were VAS pain, pain frequency, morning-stiffness duration, DAPSA and sex.
Conclusions
ML models built on routine variables can identify patients with PsA who have clinically significant CS symptom burden, with good internal and acceptable performance on preliminary external validation. LR and RF performed comparably, with LR offering a transparent, interpretable model and RF greater modelling flexibility. Such models may become an easily implemented assessment of elevated CS symptom burden in clinical practice for PsA patients’ management, pending further validation in larger, more diverse cohorts.
Zitieren
APA
Frascà, L., Salmè, M., Currado, D., Saracino, F., Lamberti, L., Giannini, G., Franco, V., Corberi, E., Trunfio, F., Vomero, M., Marino, A., Berardicurti, O., Vincenzo, F. D., Ruscitti, P., Cipriani, P., Gentileschi, S., Terribili, R., Tecce, F., Sicilia, R., …, & Navarini, L. (2026). Development and external validation of a machine learning model to predict central sensitization symptom burden in psoriatic arthritis. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.2013699
Vancouver
Frascà L, Salmè M, Currado D, Saracino F, Lamberti L, Giannini G, et al. Development and external validation of a machine learning model to predict central sensitization symptom burden in psoriatic arthritis. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.2013699
BibTeX
@article{Frasc2026,
author = {Frascà, Leonardo and Salmè, Marco and Currado, Damiano and Saracino, Francesca and Lamberti, Ludovica and Giannini, Guglielmo and Franco, Vanda and Corberi, Erika and Trunfio, Francesca and Vomero, Marta and Marino, Annalisa and Berardicurti, Onorina and Vincenzo, Francesco De and Ruscitti, Piero and Cipriani, Paola and Gentileschi, Stefano and Terribili, Riccardo and Tecce, Francesca and Sicilia, Rosa and Guarrasi, Valerio and Soda, Paolo and Giacomelli, Roberto and Navarini, Luca},
title = {Development and external validation of a machine learning model to predict central sensitization symptom burden in psoriatic arthritis},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.2013699}
}
EUVIMED